Antidiabetic medications and risk of cognitive disorders in type 2 diabetes: A retrospective cohort study
Ahmad Basil Nasir, Yassine Kilani, Mohammad Aldiabat, Omar Abdelghany, Youssef Hafez, Nitin Desai, Mahmoud Y Madi, Francis G Wade · 2026
Read Antidiabetic medications and risk of cognitive disorders in type 2 diabetes: A retrospective cohort study by Ahmad Basil Nasir, Yassine Kilani, Mohammad Aldiabat, Omar Abdelghany, Youssef Hafez, Nitin Desai, Mahmoud Y Madi, Francis G Wade (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0356138.txt.
Description
Ahmad Basil Nasir and colleagues mined American electronic health records for more than one and a half million adults with type 2 diabetes. They asked whether the diabetes drug a person takes tracks with later cognitive decline. Their 2026 retrospective study matched patients across five regimens, with metformin alone as the yardstick. It followed diagnoses of mild cognitive disorder, Alzheimer's disease, and vascular dementia over up to fourteen years.
Adding a GLP-1 drug to metformin was linked to roughly half the risk of vascular dementia and Alzheimer's. It was also linked to a lower rate of mild impairment. Adding an SGLT-2 drug cut vascular dementia only. Insulin alone looked worst on every outcome, likely reflecting more severe disease. The authors stress records show association, not proof.
Catalog record
| CREATOR | Ahmad Basil Nasir, Yassine Kilani, Mohammad Aldiabat, Omar Abdelghany, Youssef Hafez, Nitin Desai, Mahmoud Y Madi, Francis G Wade |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 31973 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |